Evidence map›Paper›PMID 26360252›Full record

ArticleClinical immunology (Orlando, Fla.)2015

Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.

Diane M Da Silva, Andrew W Woodham, Joseph G Skeate, Laurie K Rijkee, Julia R Taylor, Heike E Brand, Laila I Muderspach, Lynda D Roman, Annie A Yessaian, Huyen Q Pham and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. CD207 Expression Level is a New Prognostic Marker for Condyloma Acuminatum.Clinical, cosmetic and investigational dermatology · 2023
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Modulation of antigen presenting cell functions during chronic HPV infection.Papillomavirus research (Amsterdam, Netherlands) · 2017
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Diane M Da SilvaNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; Department of Obstetrics & Gynecology, University of Southern California, Los Angeles, CA, USA. Electronic address: Diane.DaSilva@med.usc.edu.
Andrew W WoodhamDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA, USA.
Joseph G SkeateNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Laurie K RijkeeGroningen International Program of Science in Medicine, University of Groningen, Groningen, The Netherlands.
Julia R TaylorDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA, USA.
Heike E BrandDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA, USA.
Laila I MuderspachNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; Department of Obstetrics & Gynecology, University of Southern California, Los Angeles, CA, USA.
Lynda D RomanNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; Department of Obstetrics & Gynecology, University of Southern California, Los Angeles, CA, USA.
Annie A YessaianNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; Department of Obstetrics & Gynecology, University of Southern California, Los Angeles, CA, USA.
Huyen Q PhamNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; Department of Obstetrics & Gynecology, University of Southern California, Los Angeles, CA, USA.
Koji MatsuoNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; Department of Obstetrics & Gynecology, University of Southern California, Los Angeles, CA, USA.
Yvonne G LinNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; Department of Obstetrics & Gynecology, University of Southern California, Los Angeles, CA, USA.
Greg M McKeeAkela Pharma Inc., Austin, TX, USA.
Andres M SalazarOncovir, Inc., Washington, D.C., USA.
W Martin KastNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; Department of Obstetrics & Gynecology, University of Southern California, Los Angeles, CA, USA; Department of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA, USA.
University of Southern California · USOncovir (United States) · USUniversity of Groningen · NL

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
VLP VACCINES AGAINST HPV INDUCED TUMORSR01CA074397 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAST, WIJBE MARTIN · 1997 to 2020
$5.5M
Exploration of novel pan-HPV treatments to block development of AIDS-associated cRC2CA148298 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAST, WIJBE MARTIN · 2009 to 2010
$1.0M
Southern California Clinical and Translational Science InstituteTL1TR000132 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2012 to 2014
$491k
NCATS NIH HHS TL1 TR000132NCATS NIH HHS TL1TR000132NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA074397NCI NIH HHS RC2 CA148298
6 · The paper itself

Abstract

Human papillomavirus (HPV)-mediated suppression of Langerhans cell (LC) function can lead to persistent infection and development of cervical intraepithelial neoplasia (CIN). Women with HPV-induced high-grade CIN2/3 have not mounted an effective immune response against HPV, yet it is unknown if LC-mediated T cell activation from such women is functionally impaired against HPV. We investigated the functional activation of in vitro generated LC and their ability to induce HPV16-specific T cells from CIN2/3 patients after exposure to HPV16 followed by treatment with stabilized Poly-I:C (s-Poly-I:C). LC from patients exposed to HPV16 demonstrated a lack of costimulatory molecule expression, inflammatory cytokine secretion, and chemokine-directed migration. Conversely, s-Poly-I:C caused significant phenotypic and functional activation of HPV16-exposed LC, which resulted in de novo generation of HPV16-specific CD8(+) T cells. Our results highlight that LC of women with a history of persistent HPV infection can present HPV antigens and are capable of inducing an adaptive T cell immune response when given the proper stimulus, suggesting that s-Poly-I:C compounds may be attractive immunomodulators for LC-mediated clearance of persistent HPV infection.

Indexed as

AdultCD8-Positive T-LymphocytesDNA, ViralFemaleHuman papillomavirus 16HumansLangerhans CellsLymphocyte ActivationMiddle AgedPapillomavirus InfectionsPoly I-CUterine Cervical DysplasiaUterine Cervical NeoplasmsDNA, ViralPoly I-CHPV16Human papillomavirusImmune evasionLangerhans cells

Identifiers

PMID26360252
PMCPMC4658296
OpenAlexW1890544725

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.